Memgen Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Series A2

  • Latest Deal Amount
  • $950K

  • Investors
  • 1

Memgen General Information

Description

Developer of viral immunotherapies designed to treat multiple cancer types. The company develops clinical-stage therapies using viral vectors to activate dendritic cells and induce anti-tumor immune responses, enabling patients with cancers like bladder, melanoma, lymphoma, lung, and liver to overcome resistance to chemotherapy.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 12 Greenway Plaza
  • Suite 1100
  • Houston, TX 77046
  • United States
+1 (832)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 12 Greenway Plaza
  • Suite 1100
  • Houston, TX 77046
  • United States
+1 (832)

Memgen Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Memgen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series A2) 10-Dec-2024 $950K Completed Clinical Trials - Phase 1
7. Later Stage VC (Series A1) 30-Jun-2023 Completed Clinical Trials - Phase 1
6. Later Stage VC (Series A) 30-Nov-2021 Completed Pre-Clinical Trials
5. Debt - General 24-Jun-2020 Completed Pre-Clinical Trials
4. Angel (individual) 23-Sep-2019 Completed Pre-Clinical Trials
3. Angel (individual) 04-Dec-2018 Completed Pre-Clinical Trials
2. Capitalization 25-Sep-2004 $6.9M $6.9M Completed Startup
1. University Spin-Out 01-Jan-2004 Completed Clinical Trials - Phase 1
To view Memgen’s complete valuation and funding history, request access »

Memgen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-1
Series A
To view Memgen’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Memgen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of viral immunotherapies designed to treat multiple cancer types. The company develops clinical-stage therapie
Drug Discovery
Houston, TX
7 As of 2025

Plymouth Meeting, PA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Memgen Competitors (32)

One of Memgen’s 32 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Allogene Therapeutics Formerly VC-backed South San Francisco, CA
Genocea Biosciences Formerly VC-backed Cambridge, MA
Sorrento Therapeutics Formerly VC-backed San Diego, CA
Ayala Pharmaceuticals Corporation Wilmington, DE
You’re viewing 5 of 32 competitors. Get the full list »

Memgen Patents

Memgen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025194221-A1 A pulmonary vaccine to prevent tuberculosis Pending 22-Mar-2024
EP-4444334-A2 Oncolytic virus boosts t cell response for effective til therapy Pending 07-Dec-2021
EP-4444334-A4 Oncolytic virus boosts t cell response for effective til therapy Pending 07-Dec-2021
US-20230270784-A1 Oncolytic virus boosts t cell response for effective til therapy Pending 07-Dec-2021
WO-2023108003-A2 Oncolytic virus boosts t cell response for effective til therapy Inactive 07-Dec-2021 A61K35/17
To view Memgen’s complete patent history, request access »

Memgen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Memgen Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
University of California, San Diego University Minority
To view Memgen’s complete investors history, request access »

Memgen FAQs

  • When was Memgen founded?

    Memgen was founded in 2004.

  • Where is Memgen headquartered?

    Memgen is headquartered in Houston, TX.

  • What is the size of Memgen?

    Memgen has 7 total employees.

  • What industry is Memgen in?

    Memgen’s primary industry is Drug Discovery.

  • Is Memgen a private or public company?

    Memgen is a Private company.

  • What is Memgen’s current revenue?

    The current revenue for Memgen is .

  • How much funding has Memgen raised over time?

    Memgen has raised $36.9M.

  • Who are Memgen’s investors?

    University of California, San Diego has invested in Memgen.

  • Who are Memgen’s competitors?

    Inovio Pharmaceuticals, Allogene Therapeutics, Genocea Biosciences, Sorrento Therapeutics, and Ayala Pharmaceuticals are some of the 32 competitors of Memgen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process